Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

13.93 -1.10 (-7.32%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Based on good technical signals, BIOHAVEN LTD is potentially setting up for a breakout.
BIOHAVEN LTD (NYSE:BHVN) showing some interesting technicals. Here's why. 
Via Chartmill
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are constantly on the hunt for undervalued, under-followed, and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Biohaven Stock Is Plunging Today - Here's Why
Biohaven Ltd (NASDAQ: BHVN) shares are down after the company announced multiple  
Via Benzinga
Why Biohaven Stock Is Crashing Today
The clinical-stage biotech is going to remain in the clinical stage longer than it hoped. 
Via The Motley Fool
Why Biohaven Stock Caught Fire This Week
Investors are excited about the company's recent progress. 
Via The Motley Fool
Recap: Biohaven Q1 Earnings
Via Benzinga
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Biohaven Stock Is Skyrocketing Today
Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain. 
Via The Motley Fool
MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
US Stocks Open Higher; Costco Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.14% to 33,664.90 while the NASDAQ... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cramer Warns Investors About This AI Company Up 146% YTD: 'Too Much Hype, Too Much Fluff'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Micron Technology, Inc. (NASDAQ: MU) is "coming out of the trough, I agree with the hype. 
Via Benzinga
Topics Artificial Intelligence
$2M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Will The Dow Make History Today With A 14 Straight?
The blue-chip index is slightly above breakeven at midday, while the S&P 500 Index and Nasdaq Composite are higher after another batch of earnings. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control. 
Via Benzinga
2 Growth Stocks With Major Incoming Catalysts
Binary events slated for July could quickly send these biotech stocks through the roof. 
Via The Motley Fool
Top 5 Health Care Stocks That May Crash This Month
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Tower Semiconductor, XP And 3 Stocks To Watch Heading Into Monday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Top 5 Best And Worst U.S. Industry ETFs In Q1 2023: AI and Bank Turmoil Shaped Stock Returns
The first quarter of 2023 was positive for the U.S. stock market as a whole, with the S&P 500 index faithfully tracked by the SPDR S&P 500 ETF Trust (ARCA: SPY), rising by 6%. 
Via Benzinga
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
Via Talk Markets
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.